SCHEMBL4343607

SCHEMBL4343607

CC(C)(C)[C@@H](NC(=O)CC(=O)N[C@H](C(C)(C)C)C(O)(Cc1ccccc1)Cc1ccccc1)C(O)(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.42
CYP3A4 P08684 2/20 0.42
CYP1A2 P05177 1/20 0.42
RECQL P46063 1/20 0.42
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
CYP2D6 P10635 1/20 0.40
MMP8 P22894 3/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
RIPK1 Q13546 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HIF1A Q16665 1/20 0.39
TACR3 P29371 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4330929 0.86 TRPA1 (0.41) TRPA1CYP3A4CYP1A2RECQLALDH1A1
SCHEMBL1152966 0.81 TRPA1 (0.38) TRPA1CYP3A4CYP1A2RECQLMAPK1
SCHEMBL4344035 0.81 TRPA1 (0.42) TRPA1CYP3A4CYP1A2RECQLALDH1A1
SCHEMBL4337791 0.81 NPC1 (0.45) TRPA1CYP3A4CYP1A2RECQLMAPK1
SCHEMBL1153431 0.79 ALDH1A1 (0.38) TRPA1CYP3A4CYP1A2RECQLALDH1A1
SCHEMBL1153351 0.79 ALDH1A1 (0.38) TRPA1CYP3A4CYP1A2RECQLALDH1A1
SCHEMBL1154076 0.78 MMP1 (0.39) TRPA1CYP3A4ALDH1A1CYP2C9CYP2C19
SCHEMBL4332569 0.78 CYP2C19 (0.44) CYP3A4CYP1A2RECQLMAPK1ALDH1A1
SCHEMBL4333077 0.77 PSMB8 (0.47) ALDH1A1LMNANPC1RAB9ACNR2
SCHEMBL4348972 0.76 MME (0.45) CYP1A2ALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612236-B2 Method for producing optically active bisamidoalcohol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-03 US disclosed
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced SUMITOMO CHEMICAL COMPANY, LIMITED 2007-05-03 US disclosed
EP-1698616-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced CCNL2, ARL1, ACSL3 TRPA1 558/4885CYP3A4 871/4885CYP1A2 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.